E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: Biological and clinical features

Robin Foa, Antonella Vitale, Marco Mancini, Antonio Cuneo, Cristina Mecucci, Loredana Elia, Romina Lombardo, Giuseppe Saglio, Giuseppe Torelli, Luciana Annino, Giorgina Specchia, Eugenio Damasio, Anna Recchia, Francesco Di Raimondo, Enrica Morra, Ettore Volpe, Agostino Tafuri, Paola Fazi, Stephen P. Hunger, Franco Mandelli

Research output: Contribution to journalArticlepeer-review

52 Scopus citations

Abstract

Molecular and cytogenetic studies performed in 305 adult acute lymphoblastic leukaemia (ALL) patients enrolled in the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multicentric protocols identified an E2A-PBX1 fusion and/or t(1;19) in 10 patients (3.3%). All had common ALL, were mostly CyIg+ and were CD34/CD13/CD33-. Nine patients achieved a complete remission (CR); five patients showed a haematological relapse after 7 months (median). Four patients are alive in first CR with a median follow-up of 29 months; three patients are molecularly negative. This abnormality is frequently associated with early treatment failure. E2A-PBX1+ adult ALL should be considered for intensified treatment strategies and monitoring of minimal residual disease.

Original languageEnglish
Pages (from-to)484-487
Number of pages4
JournalBritish Journal of Haematology
Volume120
Issue number3
DOIs
StatePublished - Feb 2003
Externally publishedYes

Keywords

  • Adult ALL
  • E2A-PBX1
  • FISH
  • T(1;19) translocation

Fingerprint

Dive into the research topics of 'E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: Biological and clinical features'. Together they form a unique fingerprint.

Cite this